Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) reports developments as an early-stage biotechnology company focused on orally administered small-molecule therapeutics for obesity and related metabolic disorders. Recent updates center on ALN1003, a non-hormonal, non-incretin oral candidate evaluated in preclinical diet-induced obesity models, including body-weight, liver and metabolic biomarker findings.
Company news also reflects Alaunos's transition from earlier TCR-T cell therapy programs for solid tumors, including the TCR-T Library trial, the Sleeping Beauty cell engineering platform and the hunTR discovery platform. Recurring corporate updates include operating results, research spending, capital-structure actions, Nasdaq listing compliance and governance changes.
Alaunos Therapeutics (Nasdaq:TCRT) reported integrated non-GLP preclinical results for ALN1003, an oral, non-hormonal obesity candidate, in diet-induced obese mice.
ALN1003 was associated with reduced body weight, fat mass, liver weight, improved insulin-resistance biomarkers and adipose endocrine signals, plus favorable liver histology. Cash totaled $0.354 million with runway into Q2 2026.
Alaunos Therapeutics (Nasdaq:TCRT) reported updated preclinical data for ALN1003, an oral metabolic candidate, in non-GLP diet-induced obesity mouse models. ALN1003 was associated with lower fasting insulin, reduced HOMA-IR, favorable adiponectin/leptin changes, and qualitative liver histology findings consistent with lower hepatic steatosis and lower NAS scores.
The data support continued preclinical development in metabolic syndrome and related conditions. As of March 31, 2026, cash and cash equivalents were about $0.354 million, with cash runway extending into Q2 2026 and plans to seek additional financing.
Valion Bio (Nasdaq: VBIO) appointed Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, effective May 4, 2026. Ms. Lackey brings nearly two decades of combined scientific, IP, clinical-stage, and Nasdaq public company experience.
Her background includes senior legal roles at Alaunos Therapeutics and Kuur Therapeutics, patent litigation experience at Winston & Strawn and Howrey, and early research roles at UT Health Science Center and MD Anderson. The hire is positioned to support Entolimod's FDA Animal Rule pathway, an ongoing capital raise, and scaling of the Velocity Bioworks CDMO in San Antonio.
Alaunos Therapeutics (Nasdaq: TCRT) reported positive non-GLP preclinical DIO mouse data for ALN1003, an oral non-hormonal obesity candidate. Key findings: dose-dependent weight loss (peak -12.9% at Day 34), marked liver-weight reductions (up to -55%), improved glucose (197 vs 320 mg/dL) and lower total cholesterol.
Company plans further preclinical, CMC, formulation work, IND-enabling studies and next-generation chemistry; cash was ~$1.9M as of Sept 30, 2025, with runway into Q2 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.